Lack of immunomodulating effect of disulfiram on HIV positive patients

TY - JOUR

T1 - Lack of immunomodulating effect of disulfiram on HIV positive patients

AU - Hørding, M

AU - Gøtzsche, P C

AU - Bygbjerg, Ib Christian

AU - Christensen, L D

AU - Faber, V

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Disulfiram (Antabuse (R)) is metabolized to two molecules of diethyldithiocarbamate, which has been reported to be an immunomodulating agent. In a double blind trial, 15 HIV antibody positive homosexual men were given daily doses of 100 mg or 400 mg of disulfiram or placebo, for 4 weeks. All had a CD4-count below 500 X 10(6)/l and/or a pokeweed mitogen response in a lymphocyte proliferation assay less than 50% of normal controls. None suffered from opportunistic infections. No significant effect of disulfiram on immunological, haematological, biochemical or clinical variables was observed in this short-term trial.

AB - Disulfiram (Antabuse (R)) is metabolized to two molecules of diethyldithiocarbamate, which has been reported to be an immunomodulating agent. In a double blind trial, 15 HIV antibody positive homosexual men were given daily doses of 100 mg or 400 mg of disulfiram or placebo, for 4 weeks. All had a CD4-count below 500 X 10(6)/l and/or a pokeweed mitogen response in a lymphocyte proliferation assay less than 50% of normal controls. None suffered from opportunistic infections. No significant effect of disulfiram on immunological, haematological, biochemical or clinical variables was observed in this short-term trial.

KW - Adjuvants, Immunologic

KW - Disulfiram

KW - HIV Seropositivity

KW - Humans

KW - Male

KW - Randomized Controlled Trials as Topic

KW - Time Factors

M3 - Journal article

C2 - 2184133

SN - 0192-0561

VL - 12

SP - 145

EP - 147

JO - International Journal of Immunopharmacology

JF - International Journal of Immunopharmacology

IS - 2

ER -